|
In Vitro Activity of the New Azole BAL4815 and other Antifungal Agents against Candida Bloodstream Isolates (click for details) |
|
|
|
In Vitro Activity of the New Azole Isavuconazole (BAL 4815) Compared with Six other Antifungal Agents against 155 Cryptococcus neoformans Isolates from Cuba (click for details) |
|
|
|
Evaluation of Etest and Disk Diffusion Methods Compared to Broth Microdilution Antifungal Susceptibility Testing of Posaconazole Against Clinical Isolates of Candida.
(click for details) |
|
|
|
Susceptibility Patterns of Candida Tropicalis (CT) Against Eight Antifungals.
(click for details) |
|
|
|
Determination of Minimum Effective Concentration (MEC) and Demonstration of Paradoxical Effect of Caspofungin against Aspergillus spp with XTT Assay.
(click for details) |
|
|
|
The Combination of Caspofungin (C) and Voriconazole (V) as Primary and Salvage Therapy of Invasive Aspergillosis (IA) in Hematologic Malignancy Patients (HMP).
(click for details) |
|
|
|
Efficacy of Voriconazole (VCZ) Against Experimental Pulmonary Aspergillosis in Japanese Quail (Coturnix japonica) .
(click for details) |
|
|
|
Caspofungin and Aspergillus Fumigatus Enhance TLR9 Expression on the Surface of PMNs.
(click for details) |
|
|
|
Variable Effects of Voriconazole (VRC) and Caspofungin (CAS) on Cytokine and Chemokine Release by Human Monocytes (MNCs) in Response to Aspergillus Fumigatus (AF).
(click for details) |
|
|
|
Histone Modifications Regulate Antifungal Sensitivity and MDR Gene Expression in Candida Glabrata.
(click for details) |
|
|
